Treating MS patients earlier in the disease progression may affect long-term outcomes 1-4
|
|
- Isabella Evans
- 5 years ago
- Views:
Transcription
1 Treating MS patients earlier in the disease progression may affect long-term outcomes 1-4 TIME DISEASE ONSET EARLY TREATMENT NATURAL COURSE OF MS LATER TREATMENT DISABILITY INCREASE The disease activity of MS should be treated as effectively as possible during the full duration of therapy, and particularly in the early course of disease 1 1
2 Introducing oral TECFIDERA: Strong efficacy for first-line treatment of RRMS Safety and efficacy demonstrated in two pivotal phase III trials in RRMS, DEFINE and CONFIRM, including over 2600 patients 5,6 Two phase III trials, including one with an active comparator arm, were conducted in order to meet approval requirements from regulatory authorities DEFINE: 2-year, randomised, double-blind, placebo-controlled phase III study in 1234 patients with RRMS CONFIRM: 2-year, randomised, double-blind, placebo-controlled phase III study in 1417 patients with RRMS, including glatiramer acetate as a reference comparator 2
3 In the DEFINE study TECFIDERA reduced the number of relapses by approximately 50% in RRMS In the primary endpoint measurement, TECFIDERA reduced the proportion of RRMS patients who relapsed by 49% 5 As shown by ARR, significant reductions vs placebo at 2 years P<0.001 DEFINE Study OVERALL POPULATION* IN DEFINE STUDY ARR Placebo (n=408) 53% 0.17 TECFIDERA 240 mg BID (n=410) ARR REDUCTION The annualised relapse rate (ARR) in each treatment group was calculated as the total number of relapses experienced in a group divided by the total number of subject-years on study at 2 years (minus the time on alternative MS medication) for that group. DEFINE: 2-year multicentre, randomised, double-blind, placebo-controlled study in 1234 patients with RRMS. 5 BID=twice a day. * Treatment-naive and previously treated patients. 3
4 In the DEFINE study TECFIDERA delayed physical disability progression As shown by EDSS, significant delay in disability progression vs placebo over 2 years 5 Proportion of Patients With Confirmed Progression Placebo (n=408) TECFIDERA 240 mg BID (n=410) HR= % CI (0.44, 0.87) P= Weeks 38% DEFINE Study REDUCTION IN DISABILITY PROGRESSION OVERALL POPULATION* IN DEFINE STUDY DEFINE: 2-year multicentre, randomised, double-blind, placebo-controlled study in 1234 patients with RRMS. 5 CI=confidence interval, EDSS=Expanded Disability Status Scale, HR=hazard ratio. * Treatment-naive and previously treated patients. 4
5 In the rater-blinded, reference comparator CONFIRM study TECFIDERA reduced ARR in RRMS As shown by ARR, significant reductions vs placebo at 2 years 6 CONFIRM Study OVERALL POPULATION* IN CONFIRM STUDY ARR Placebo (n=363) 29% 0.29 P=0.01 Glatiramer acetate SC 20 mg QD (n=350) ARR Placebo (n=363) 44% 0.22 P<0.001 TECFIDERA 240 mg BID (n=359) ARR REDUCTION CONFIRM: 2-year multicentre, randomised, double-blind, placebo-controlled study in 1417 patients with RRMS. 6 BID=twice a day QD=once a day. * Treatment-naive and previously treated patients. 5
6 Physical disability progression with TECFIDERA As shown by EDSS, delay in disability progression vs placebo over 2 years 5,6 DEFINE Study CONFIRM Study Proportion of Patients With Confirmed Progression Placebo (n=408) HR= % CI (0.44, 0.87) P=0.005 REDUCTION IN DISABILITY 38% PROGRESSION 0.16 TECFIDERA 240 mg BID (n=410) Proportion of Patients With Confirmed Progression Placebo (n=363) HR= % CI ( ) P= % REDUCTION IN DISABILITY PROGRESSION 0.13 (NOT SIGNIFICANT) TECFIDERA 240 mg BID (n=359) OVERALL POPULATION* IN DEFINE AND CONFIRM STUDIES DEFINE: 2-year multicentre, randomised, double-blind, placebo-controlled study in 1234 patients with RRMS. 5 CONFIRM: 2-year multicentre, randomised, double-blind, placebo-controlled study in 1417 patients with RRMS. 6 BID=twice a day * Treatment-naive and previously treated patients. 27% AND 17% OF PLACEBO-TREATED PATIENTS EXPERIENCED DISABILITY PROGRESSION IN THE DEFINE AND CONFIRM STUDIES, RESPECTIVELY 5,6 6
7 In the DEFINE study TECFIDERA reduced ARR in treatment-naive patients TREATMENT-NAIVE PATIENTS* IN DEFINE STUDY Treatment-naive patients: significant reduction in ARR vs placebo at 2 years 7 ARR P< Placebo (n=181) 67% 0.09 TECFIDERA 240 mg BID (n=187) ARR REDUCTION DEFINE Study 46% OF BID PATIENTS IN DEFINE HAD NOT RECEIVED ANY PRIOR MS MEDICATION DEFINE: 2-year multicentre, randomised, double-blind, placebo-controlled study in 1234 patients with RRMS. 5 * Had not received prior medication for the treatment of MS. 7
8 In the DEFINE study TECFIDERA delayed physical disability progression in treatment-naive patients As shown by EDSS, significant reduction in 12-week disability progression vs placebo at 2 years 7 Proportion of Patients With Confirmed Progression P< Placebo (n=181) 62% 0.12 TECFIDERA 240 mg BID (n=187) REDUCTION IN DISABILITY PROGRESSION DEFINE Study 46% OF BID PATIENTS IN DEFINE HAD NOT RECEIVED ANY PRIOR MS MEDICATION DEFINE: 2-year multicentre, randomised, double-blind, placebo-controlled study in 1234 patients with RRMS. 5 TREATMENT-NAIVE PATIENTS* IN DEFINE STUDY * Had not received prior medication for the treatment of MS. 8
9 In the DEFINE study TECFIDERA reduced MRI activity Significant reductions vs placebo in incidences of Gd+ lesions, new or newly enlarging T2 lesions, and new T1 hypointense lesions at 2 years 5,8 Gd+ T2 1.8 P<0.001 P< T1 DEFINE Study P< Mean Number of Gd+ Lesions Placebo (n=165) 90% RELATIVE ODDS REDUCTION OF GD+ LESIONS AT 2 YEARS 0.1 TECFIDERA 240 mg BID (n=152) Mean Number of New or Newly Enlarging T2 Lesions Placebo (n=165) 85% RELATIVE REDUCTION OF NEW OR NEWLY ENLARGING T2 LESIONS 2.6 TECFIDERA 240 mg BID (n=152) Mean Number of New T1 Hypointense Lesions Placebo (n=165) 72% RELATIVE REDUCTION OF NEW T1 LESIONS 2.0 TECFIDERA 240 mg BID (n=152) DEFINE: 2-year multicentre, randomised, double-blind, placebo-controlled study in 1234 patients with RRMS. 5 In the CONFIRM study Patients experienced consistent, statistically significant reductions in the incidence of MRI-confirmed lesions 6 TECFIDERA reduced the number of Gd+ lesions by 74%, T2 lesions by 71%, and T1 lesions by 57% vs placebo at 2 years (P<0.0001) 6 9
10 In the DEFINE study TECFIDERA: strong efficacy for first-line treatment of RRMS ARR 53 % Proven reduction in relapse rates at 2 years 5 Gd+* 90 % MRI T2* 85 % Reduced brain lesions in a broad range of MRI measures 5,8 T1 72 % EDSS 38 % Delayed progression of physical disability 5 (P<0.001) *(P<0.001) (P<0.0001) (P=0.005) TECFIDERA: a combination of strong efficacy and treatment simplicity for first-line treatment in RRMS patients 10
11 DEFINE: Change in Whole Brain Volume Baseline to Year 2 Week 24 to Year 2 Median % Change in Whole Brain Volume %* % NS %* 5% NS Placebo (n=163) BG mg BID (n=151) BG mg TID (n=152) 11
12 CONFIRM: Change in Whole Brain Volume 10 Median % Change in Whole Brain Volume Change from Baseline to Year 2 Change from Week 24 to Year % P= % P= % P= % P= % P= % P= Placebo (n=144) BG mg BID (n=147) BG mg TID (n=143) GA (n=161) 12
13 ENDORSE Post Marketing ongoing study Efficacy: Time to First Relapse DEFINE, CONFIRM, and ENDORSE Integrated Analysis (ITT Population) 13 Probability of Relapse DEFINE and CONFIRM PBO/DMF TID PBO/DMF BID GA/DMF TID GA/DMF BID DMF TID/DMF TID DMF BID/DMF BID ENDORSE Proportion Relapsed at 4 Years Baseline 12 Patients at Risk Time on Study (weeks) DMF BID/DMF BID DMF TID/DMF TID PBO/DMF BID PBO/DMF TID GA/DMF BID GA/DMF TID Only objective relapses were included in the Kaplan-Meier estimate analysis; patients who did not experience a relapse prior to switching
14 ENDORSE Post Marketing ongoing study Efficacy: Time to Disability Progression by EDSS (24-Week Confirmation) DEFINE, CONFIRM, and ENDORSE Integrated Analysis (ITT Population) 14 Probability of Confirmed Disability Progression DEFINE and CONFIRM PBO/DMF TID PBO/DMF BID GA/DMF TID GA/DMF BID DMF TID/DMF TID DMF BID/DMF BID ENDORSE Proportion Progressed at 4 Years Baseline 12 Patients at Risk DMF BID/DMF BID DMF TID/DMF TID PBO/DMF BID PBO/DMF TID GA/DMF BID GA/DMF TID Time on Study (weeks)
15 TECFIDERA showed a manageable tolerability profile Gastrointestinal (GI) and flushing events were the most common adverse events 8 Adverse event* Placebo TECFIDERA 240 mg BID Diarrhoea 10% 14% Nausea 9% 12% Upper abdominal pain 6% 10% Abdominal pain 4% 9% Vomiting 5% 8% Dyspepsia 3% 5% Flushing 4% 34% * For other adverse events please see label. These events were mostly mild to moderate 8 GI and flushing events tended to begin early in the course of treatment (primarily in month 1) 8 For patients who experience these events, they may continue to occur intermittently throughout TECFIDERA treatment 15
16 Integrated Analysis: Incidence of Flushing Events* and Gastrointestinal Events by Study Month Patients (%) Patients (%) Flushing Events Placebo (n=408) BG mg BID (n=410) BG mg TID (n=416) Month Gastrointestinal Events Month *Flushing events include the preferred terms flushing, hot flush, erythema, generalized erythema, burning sensation, skin burning sensation, feeling hot, and hyperemia; gastrointestinal events include the preferred terms in the level 2 subordinate standardized MedDRA queries gastrointestinal nonspecific inflammations or gastrointestinal nonspecific symptoms and therapeutic procedures. BID=twice daily; TID=3 times daily. Selmaj K et al. Presented at ECTRIMS; October 10 13, 2012; Lyon, France. P
17 Measures designed to help minimize GI and flushing adverse events Measures to improve tolerability 8 GI Flushing Starting dose of 120 mg twice a day for 7 days Temporary dose reduction of TECFIDERA to 120 mg BID; within 1 month, the recommended dose of 240 mg BID orally should be resumed Taking with food Administration of 325-mg (or equivalent) non-enteric coated aspirin* prior to TECFIDERA dosing * Long-term use of aspirin is not recommended for the management of flushing. Potential risks associated with aspirin should be considered prior to co-administration with TECFIDERA. 8 17
18 DEFINE: Lymphocyte Counts Mean Lymphocyte Count ( 10 9 /L) Placebo BG mg BID BG mg TID LLN BL Visit (weeks) n=407 (baseline) to 245 (week 96) n=410 (baseline) to 271 (week 96) n=416 (baseline) to 268 (week 96) Hematology Parameters: Mean Values over Time Placebo BG mg BID BG mg TID Note: LLN is lower limit in standard unit; if multiple values were given for LLN of any parameter, the highest LLN is shown. DEFINE=Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-Remitting MS; BID=twice daily; TID=3 times daily; LLN=lower limit of normal; BL=baseline; MS=multiple sclerosis. Biogen Idec, data on file. 18
19 Low discontinuation due to incidence of GI and flushing events Events leading to discontinuation 8 TECFIDERA 240 mg BID GI 4% Flushing 3% THE INCIDENCE OF GI AND FLUSHING (THE MOST COMMON ADVERSE EVENTS) LEADING TO DISCONTINUATION WAS GENERALLY LOW 8 19
20 TECFIDERA showed a favourable safety profile 8 The overall incidences of renal adverse reactions were similar for TECFIDERA and placebo There was a small difference between TECFIDERA BID (9%) and placebo (7%) for proteinuria Infection risk and serious infection rate with TECFIDERA were comparable with placebo No increased incidence of serious infections observed in patients with lymphocyte counts <0.8x10 9 /l or <0.5x10 9 /l Lymphocyte counts decreased by approximately 30% over the first year, then plateaued Mean and median lymphocyte counts remained within normal limits The long-term, clinical significance of these effects is not known. 20
21 In clinical trials, a total of 2468 patients have received TECFIDERA and been followed for periods up to 4 years with an overall exposure equivalent to 3588 person-years 8 Approximately 1056 patients have received more than 2 years of treatment with TECFIDERA The experience in uncontrolled clinical trials isconsistent with the experience in the placebocontrolled clinical trials 21
22 Monitoring requirements 8 Complete blood counts Hepatic function tests Every 6 to 12 months thereafter and as clinically indicated Renal function tests Month O AFTER 6 MONTHS, ASSESSMENTS CAN BE ACCOMPLISHED WITH A SINGLE BLOOD DRAW AND URINE SAMPLE AT 6- TO 12-MONTH INTERVALS AND AS CLINICALLY INDICATED 22
23 In the DEFINE study TECFIDERA: a new oral treatment for RRMS patients offering strong efficacy, manageable tolerability, and a favourable safety profile STRONG EFFICACY YOU WANT FOR FIRST-LINE TREATMENT 5 ARR Proven reduction in relapse rates at 2 years EDSS Delayed progression of physical disability MRI Reduced brain lesions in a broad range of MRI measures ARR 53 % (P<0.001) EDSS 38 % (P=0.005) Gd+ 90 % (P<0.001) REDUCTION IN RELAPSE RATES REDUCTION OF PHYSICAL DISABILITY T2 85 % (P<0.001) 23
24 SIMPLICITY THEY NEED FOR FIRST-LINE TREATMENT 7 SAFETY AND MONITORING Favourable safety profile with monitoring aligned with clinical practice TWICE-DAILY ORAL DOSING Day Night 24
25 TECFIDERA oral dosing Start with Continue with am 120 mg pm 120-mg capsules have a green cap and white body printed with BG mg in black ink on the body 8 am pm 240 mg 240-mg capsules have a green cap and a green body printed with BG mg in black ink on the body 8 Twice-daily TECFIDERA should be taken with food morning and evening 25
26 1. Gold R, Hartung H-P, Stangel M, Wiendl H, Zipp F. Therapeutic goals of platform and escalation therapies for relapsing-remitting multiple sclerosis. Akt Neurol. 2012;39: Leray E, Yaouang J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133: Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20): Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126: Gold G, Kappos L, Arnold DL, et al; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12): Fox RJ, Miller DH, Phillips JT, et al; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12): Bar-Or A, Gold R, Kappos L, et al. Effect of BG-12 in subgroups of patients with relapsing remitting multiple sclerosis: findings from the DEFINE study. Poster presented at: 64th Annual Meeting of the American Academy of Neurology; April 21-28, 2012, New Orleans; LA. P TECFIDERA Summary of Product Characteristics. Biogen Idec. 9. *P<0.05 vs placebo, based on ANCOVA on ranked data, adjusted for region and normalized brain volume at baseline/week 24. DEFINE=Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-Remitting MS; NS=not statistically significant vs placebo; BID=twice daily; TID=3 times daily; ANCOVA=analysis of covariance; MS=multiple sclerosis. Arnold DL et al. Presented at AAN; April 21 28, 2012; New Orleans, LA. S CONFIRM=Comparator and an Oral Fumarate in Relapsing-Remitting MS; BID=twice daily; TID=3 times daily; GA=glatiramer acetate; MS=multiple sclerosis. Biogen Idec, data on file. 11. Adjusted mean and 95% CI based on negative binomial regression, adjusted for region and baseline volume of T2 lesions at the start of DEFINE and CONFIRM; data after subjects switched to alternative MS medications were excluded. DMF, dimethyl fumarate. Miller DH, et al. Presented at: ECTRIMS, October 2 5, 2013, Copenhagen, Denmark. Poster P The MOGISS reflects the impact of GI-related events on the patient during the 24 hours prior to data entry. P Fox EJ et al, P2.227 AAN Only objective relapses were included in the Kaplan-Meier estimate analysis; patients who did not experience a relapse prior to switching to alternative MS medications or withdrawal from study were censored at the time of switch/withdrawal. *Two years in DEFINE/CONFIRM and 2 years in ENDORSE. DMF, dimethyl fumarate. Gold R, et al. Presented at: ECTRIMS, October 2 5, 2013, Copenhagen, Denmark. Poster P Subjects were censored if they withdrew from study or switched to alternative MS medication without a progression. DMF, dimethyl fumarate. Gold R, et al. Presented at: ECTRIMS, October 2 5, 2013, Copenhagen, Denmark. Poster P Dimethyl Fumarate: A review of its use in patients with Relapsing- Remitting Multiple Sclerosis Celeste B. Burness- Emma D. Decks CNS Drugs DOI /s published online: March 13th
Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients
Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients Author and Contact details: Responsible Director: Ian Pomeroy Service lead for MS. Tel: (0151) 529 5715 Email: ian.pomeroy@thewaltoncentre.nhs.uk
More informationCurrent Enrolling Clinical Trials
ASSESS RRMS patients with active disease who are still able to walk. Mariko Kita MD Description of Study/Trial: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety
More informationEfficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
RESEARCH ARTICLE Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials Vissia Viglietta 1, David Miller 2, Amit Bar-Or 3, J.
More informationTECFIDERA is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.
AUSTRALIAN PRODUCT INFORMATION TECFIDERA (dimethyl fumarate) modified release capsules 1 NAME OF THE MEDICINE Dimethyl fumarate (DMF). 2 QUALITATIVE AND QUANTITATIVE COMPOSITION TECFIDERA (dimethyl fumarate
More informationABSTRACT ORIGINAL RESEARCH. Ralf Gold. Gavin Giovannoni. J. Theodore Phillips. Robert J. Fox. Annie Zhang. Jing L. Marantz
Neurol Ther (2016) 5:45 57 DOI 10.1007/s40120-016-0042-8 ORIGINAL RESEARCH Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing Remitting Multiple Sclerosis:
More informationProgress in the field
Progress in the field Eva Havrdová Charles University in Prague 1st Medical Faculty and General University Hospital Disclosures Dr. Havrdová has received consulting fees from Actelion, Biogen Idec, Merck,
More informationAdvances in the Management of Multiple Sclerosis: A closer look at novel therapies. Disclosures
Advances in the Management of Multiple Sclerosis: A closer look at novel therapies Lily Jung Henson, MD, MMM, FAAN Chief of Neurology Piedmont Healthcare, Atlanta, GA National Association of Managed Care
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tecfidera 120 mg gastro-resistant hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 120 mg dimethyl
More information2013 MS Phenotype Descriptions: Relapsing MS 1
2013 MS Phenotype Descriptions: Relapsing MS 1 Disease-Modifying Therapies? which can be found in its entirety at. Clinically isolated syndrome (CIS) Not Active a Active a,b Relapsing-remitting disease
More informationWhen choosing among treatments for
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate J. Theodore Phillips, MD, PhD; Krzysztof Selmaj, MD, PhD;
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationABSTRACT ORIGINAL RESEARCH. Hirofumi Ochi. Masaaki Niino. Yasuhiro Onizuka. Katsutoshi Hiramatsu. Masakazu Hase. Jang Yun. André Matta.
Adv Ther (2018) 35:1598 1611 https://doi.org/10.1007/s12325-018-0788-8 ORIGINAL RESEARCH 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis:
More informationClinician s view of Benefit-Risk
Clinician s view of Benefit-Risk Gordon Francis, MD Novartis, Clinical Development Clinician s View of Benefit-Risk: a need for reliable metrics A tale of 3 drugs Natalizumab MS Crohn s Disease Fingolimod
More informationMS Academia: Multiple sclerosis advanced course
13 September 2016 - London, UK MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Robert J. Fox Assessment of treatment response IMPROVING
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationMedication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationMEDIA BACKGROUNDER. Teriflunomide: A novel oral drug being investigated for the treatment of Multiple Sclerosis (MS)
MEDIA BACKGROUNDER Teriflunomide: A novel oral drug being investigated for the treatment of Multiple Sclerosis (MS) 1. Background Teriflunomide is a new oral disease-modifying therapy (DMT), discovered
More informationRéférence bibliographique. "Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis."
"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis." Gold, Ralf ; Kappos, Ludwig ; Arnold, Douglas L ; Bar-Or, Amit ; Giovannoni, Gavin ; Selmaj, Krzysztof ; Tornatore, Carlo
More informationTreatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis
Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis This protocol provides monitoring guidance for adult patients requiring Dimethyl fumarate therapy
More informationMRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis. E.W. Radue K. Bendfeldt Till Sprenger
MRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis E.W. Radue K. Bendfeldt Till Sprenger Medical Image Analysis Center University Hospital Basel www. miac.ch
More informationXP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED.
XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR DISCLAIMER These slides and the accompanying oral
More informationTRANSPARENCY COMMITTEE Opinion 05 March 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 05 March 2014 AUBAGIO 14 mg, film-coated tablet B/28 tablets (CIP: 3400927499890) Applicant: GENZYME SAS INN ATC code
More informationTECFIDERA (dimethyl fumarate) delayed-release capsules, for oral use Initial U.S. Approval: 2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TECFIDERA safely and effectively. See full prescribing information for TECFIDERA. TECFIDERA (dimethyl
More information1. ABSTRACT. PASS Clinical Study Report Version 1.0
1. ABSTRACT Title A Retrospective, Multi-Center, Observational Study to Assess the Effect of Tecfidera Delayed-Release Capsules on Lymphocyte Subsets in Subjects with Relapsing Forms of Multiple Sclerosis
More informationTECFIDERA PRODUCT MONOGRAPH. Dimethyl fumarate delayed-release capsules. 120 mg and 240 mg. Other Nervous System Drug
PRODUCT MONOGRAPH Pr TECFIDERA Dimethyl fumarate delayed-release capsules 120 mg and 240 mg Other Nervous System Drug Biogen Canada Inc. 90 Burnhamthorpe Road West, Suite 1100 Mississauga, Ontario L5B
More informationSupplementary Online Content
Supplementary Online Content Kappos L, Li DKB, Stüve O, et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the
More informationMitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA Disclosures Consultant and Speaker Bureau member for Biogen-Idec, Pfizer, TEVA Neuroscience, Bayer, EMD Serrono, Questcor, Novartis,
More informationBruce Cree, MD, PhD, MCR. BG-12 Has Shown Nrf2 Pathway. Activation. DEFINE (BG-12/Dimethyl Fumarate) : Study Design
MS Therapies Update 212 Bruce Cree, MD, PhD, MCR BG12 Alemtuzumab Daclizumab BAF312 Erythropoetin Outline Fingolimod IFN β-1a Natalizumab Oral solumedrol Duloxetine O BG-12 Has Shown Nrf2 Pathway O OH
More information1996 vs 2013 MS Phenotype Descriptions of Progressive Disease
Learning Objectives Upon completion, participants should be able to: Describe methods of distinguishing among RRMS, SPMS, and PPMS Incorporate available evidence about emerging and recently approved novel
More informationRegulatory Status FDA-approved indication: Tecfidera is indicated for the treatment of patients with relapsing forms of multiple sclerosis (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.01 Subject: Tecfidera Page: 1 of 5 Last Review Date: December 2, 2016 Tecfidera Description Tecfidera
More informationMS Academia: Multiple sclerosis advanced course
6 October 2015 - Barcelona, Spain MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Mark S. Freedman University of Ottawa and the Ottawa
More informationEAN Amsterdam June 23-27, 2017
EAN 2017 Amsterdam June 23-27, 2017 MS Nowadays-new goals Giancarlo Comi Dept. of Neurology & Institute of Experimental Neurology Università Vita Salute S.Raffaele, Milano European Charcot Foundation Disclosure
More informationThe natural history of multiple sclerosis (MS) Dimethyl Fumarate
Dimethyl Fumarate A Review of Efficacy and Practical Management Strategies for Common Adverse Events in Patients with Multiple Sclerosis J. Theodore Phillips, MD, PhD; Stephanie Agrella, NP; Robert J.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tecfidera 120 mg gastro-resistant hard capsules Tecfidera 240 mg gastro-resistant hard capsules 2. QUALITATIVE AND QUANTITATIVE
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 July 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 July 2011 GILENYA 0.5 mg, hard capsules, perforated unit dose blister packs B/7 (CIP code: 417 785-3) GILENYA 0.5
More informationCircle Yes or No Y N. [If no, skip to question 8.] 2. Has the patient been compliant with therapy as verified by the prescriber?
06/01/2016 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Tecfidera (MI88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationLocal Natalizumab Treatment Protocol
Local Natalizumab Treatment Protocol 1. New medicine name: Natalizumab 300mg concentrate for solution for infusion (Natalizumab ) 2. Licensed indication(s): Natalizumab is indicated for single disease
More informationMEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease
MEDIA BACKGROUNDER Multiple Sclerosis: A serious and unpredictable neurological disease Multiple sclerosis (MS) is a complex chronic inflammatory disease of the central nervous system (CNS) that still
More informationVesicular Demyelination in MS A Pattern of Humoral Immune Pathology Multiple Sclerosis: B-Cells Take Center Stage
Vesicular Demyelination in MS A Pattern of Humoral Immune Pathology Multiple Sclerosis: B-Cells Take Center Stage Stephen L. Hauser, M.D. CD2 B cells in an MS lesion CD2 B cells in an MS lesion 1 CD138
More informationPatient 1: 31-Year-Old Female. Fingolimod treatment
Cell Counts (10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Lymphocyte Pharmacodynamics and Safety of Use in Patients Previously
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationHot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018
Hot Topics Multiple Sclerosis Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018 Disclosures Natalie Parks has received compensation from Biogen, EMD Serono, Roche, and Sanofi
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDouglas L. Arnold 1,2, Peter A. Calabresi 3, Bernd C. Kieseier 4,5, Shifang Liu 5, Xiaojun You 5, Damian Fiore 5 and Serena Hung 5*
Arnold et al. BMC Neurology (2017) 17:29 DOI 10.1186/s12883-017-0799-0 RESEARCH ARTICLE Open Access Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Use of MRI in Clinical Decision- Making
More informationCost-effectiveness of cladribine (Mavenclad ) for the
Cost-effectiveness of cladribine (Mavenclad ) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features The NCPE has issued a recommendation
More informationAlemtuzumab Clinical Information for Nurses. Lemtrada
Alemtuzumab Clinical Information for Nurses Lemtrada Objectives Upon completion of this program, the learner will: Understand mechanism of action of Lemtrada Identify appropriate clinical situations for
More informationKaspar Rufibach Methods, Collaboration, and Outreach Group (MCO) Department of Biostatistics, Roche Basel
Construction of an Estimand in a Clinical Trial on Progressive Multiple Sclerosis Kaspar Rufibach Methods, Collaboration, and Outreach Group (MCO) Department of Biostatistics, Roche Basel Acknowledgments
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSwitching from natalizumab to fingolimod: an observational study
Acta Neurol Scand 2013: 128: e6 e10 DOI: 10.1111/ane.12082 Ó 2013 John Wiley & Sons A/S ACTA NEUROLOGICA SCANDINAVICA Clinical Commentary Switching from natalizumab to fingolimod: an observational study
More informationSynopsis. Clinical Report Synopsis for Protocol Name of Company: Otsuka Pharmaceutical Development & Commercialization, Inc.
Synopsis Clinical Report Synopsis for Protocol 197-02-220 Name of Company: Otsuka Pharmaceutical Development & Commercialization, Inc. Name of Product: Tetomilast (OPC-6535) Study Title: A Phase 3, Multicenter,
More informationProgressive Multiple Sclerosis
Progressive Multiple Sclerosis Definitions, Clinical Course and Emerging Therapies M. Mateo Paz Soldán, MD, PhD Neurology Service, VA Salt Lake City HCS Assistant Professor of Neurology, University of
More informationUnderstanding your Tecfidera. treatment. Information for patients who have been prescribed treatment with Tecfidera.
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. Contents Treatment with Tecfidera About Multiple Sclerosis (MS) Multiple sclerosis A brief
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 2, by the Massachusetts Medical Society VOLUME 343 N OVEMBER 16, 2 NUMBER 2 RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS CHRISTIAN CONFAVREUX,
More informationUpdate in Multiple Sclerosis
Update in Multiple Sclerosis Kyle Smoot, MD Providence MS Center Portland, OR 1 Disclosures Research funds from Biogen. Consulting fees from Acorda, Biogen, EMDSerono, Genzyme, Novartis, and Teva. 2 Outline
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationA Glimpse at Immunomodulators in MS
A Glimpse at Immunomodulators in MS An Interview with Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC Multiple Sclerosis Research Unit, University of Ottowa, Ottowa Canada Ottawa Hospital Research Institute,
More informationLife Long Brain Health and DMT Comparative Effectiveness
Life Long Brain Health and DMT Comparative Effectiveness Timothy Vollmer, MD Professor of Neurology University of Colorado Denver Medical Director- RMMSC and Co-Director Rocky Mountain MS Center at CU
More informationAFFIRM IN FOCUS AN INTERACTIVE OVERVIEW START HERE
AFFIRM IN FOCUS AN INTERACTIVE OVERVIEW START HERE INTENDED USE The information in this module is being provided to you to increase your knowledge and understanding of the AFFIRM a study. Although this
More informationPediatric MS treatments: What do you start with, when do you switch?
Pediatric MS treatments: What do you start with, when do you switch? Tim Lotze, M.D. Associate Professor of Pediatric Neurology Texas Children s Hospital Baylor College of Medicine Disclosures Clinical
More informationPositive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Media Release Basel 21 December 2016 Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationTherapeutic Advances in Neurological Disorders. Original Research
768775TAN0010.1177/1756286418768775Therapeutic Advances in Neurological DisordersR Gold, E Schlegel research-article20182018 Therapeutic Advances in Neurological Disorders Original Research Incidence and
More informationProgress in MS: Current and Emerging Therapies. Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada Today s Discussion Natural History and Classification of MS Treating MS Management
More informationFINGOLIMOD (GILENYA) CLINICIAN INFORMATION
What is the medication? Generic: Fingolimod Brand name: Gilenya First oral medication approved by the Food and Drug Administration (FDA) to modify the disease course in multiple sclerosis (MS) Has the
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
2 CLINICAL STUDY SYNOPSIS FINAL REPORT N0. CCD-0402-RS-0002 Title of the study: Evaluation of the 24-hour trough FEV 1 following 7 days of dosing with 2 µg once daily. A multicentre, double-blind, double-dummy,
More informationPer Soelberg Sørensen
Per Soelberg Sørensen Danish Multiple Sclerosis Center Department of Neurology Rigshospitalet, University of Copenhagen Copenhagen, Denmark Declared receipt personal compensation for serving on scientific
More informationMellen Center Approach to Ocrelizumab (Ocrevus)
Mellen Center Approach to Ocrelizumab (Ocrevus) Q: What is mechanism of action of ocrelizumab? A; Ocrelizumab is a novel humanized monoclonal anti-cd20 antibody constructed with recombinant DNA techniques
More informationPresented at the Annual Congress of ECTRIMS, October 11, 2018, Berlin, Germany
Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mab), in Patients with Relapsing Forms of Multiple Sclerosis
More informationEuropean Commission Grants Approval for Mavenclad (Cladribine Tablets)
Your Contact Friederike Segeberg +49 6151 72-6328 Investor Relations +49 6151 72-3321 August 25, 2017 European Commission Grants Approval for Mavenclad (Cladribine Tablets) First oral short-course treatment
More informationBiologics and Beyond: Treatment of Multiple Sclerosis. Rita Jebrin, PharmD, BCPS
Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS Disclosure Information Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS I have no financial
More informationDaclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
The new england journal of medicine Original Article versus Interferon Beta-1a in Relapsing Multiple Sclerosis L. Kappos, H. Wiendl, K. Selmaj, D.L. Arnold, E. Havrdova, A. Boyko, M. Kaufman, J. Rose,
More informationHealth-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
CNS Drugs (2017) 31:585 602 DOI 10.1007/s40263-017-0444-x REVIEW ARTICLE Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs Peter Joseph Jongen 1,2 Published
More informationTop 10 Research Findings of 2016
Top 10 Research Findings of 2016 NMSS Regional Summit 2017 June 10, 2017 Rebecca Spain, MD, MSPH VA Portland Health Care System Oregon Health & Science University Disclosures Research support: NMSS Department
More informationClinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org What
More informationTechnology appraisal guidance Published: 28 May 2014 nice.org.uk/guidance/ta312
Alemtuzumab for treating relapsing-remitting multiple sclerosis Technology appraisal guidance Published: 28 May 2014 nice.org.uk/guidance/ta312 NICE 2017. All rights reserved. Subject to Notice of rights
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationAnisha Keshavan. Roland Henry, PhD. Proportion of Patients (%) Rituximab 2000mg (n=66) Placebo (n=35)
Two Faces of Multiple Sclerosis February 8, 217 5 T H A N N U A L R E C E N T A D V A N C E S I N N E U R O L O G Y B CELL THERAPY FOR MULTIPLE SCLEROSIS: A NEW DAY? Inflammation Relapsing MS Anisha Keshavan
More informationNovartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis real-world data at AAN confirms
More informationOral Methylnaltrexone for the. Constipation in Patients with Chronic Non-cancer Pain
Oral Methylnaltrexone for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Richard L. Rauck, 1 John F. Peppin, 2 Robert J.Israel, 3 Jennifer Carpenito, 3 Jeffrey Cohn,
More informationThe Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study
2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers May 27 30, 2015 Indianapolis, IN The Effects of Daclizumab High Yield Process () on Patient Centered Functional Outcomes: Results From
More informationEfficacy convenience of MS treatments. Xavier Montalban Department of Neurology-Neuroimmunology. ECF Baveno 2013
Efficacy convenience of MS treatments Xavier Montalban Department of Neurology-Neuroimmunology ECF Baveno 2013 Disclaimer Dr. Montalban has received speaking honoraria and travel expenses for scientific
More informationEverolimus for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT
for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT Thank you very much for the opportunity to submit additional analysis in relation to the above technology appraisal
More informationRada Savic 1 Alain Munafo 2, Mats Karlsson 1
Population Pharmacodynamics of Cladribine Tablets Therapy in Patients with Multiple Sclerosis: Relationship between Magnetic Resonance Imaging and Clinical Outcomes Rada Savic 1 Alain Munafo 2, Mats Karlsson
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationUrgent Clinical Commissioning Policy Statement: Alemtuzumab for treating relapsingremitting. sclerosis third cycle (all ages)
Urgent Clinical Commissioning Policy Statement: Alemtuzumab for treating relapsingremitting multiple sclerosis third cycle (all ages) NHS England Reference: 170075P 1 Equality statement Promoting equality
More informationMULTIPLE SCLEROSIS - REVIEW AND UPDATE
MULTIPLE SCLEROSIS - REVIEW AND UPDATE Luka Vlahovic, MD Neuroimmunology/Multiple Sclerosis Creighton University Medical Center MS is primary demyelinating disease of the central nervous system. MS is
More informationFingolimod for the treatment of Relapsing-Remitting Multiple Sclerosis
Novartis Neurosciences Therapeutic Area Fingolimod for the treatment of Relapsing-Remitting Multiple Sclerosis Renato Turrini Medical Head Franchise Neurosciences Milano, 22 giugno 2017 What is RWE? Real-world
More informationManaging the Expanding Matrix of MS Therapies: The Orals
Managing the Expanding Matrix of MS Therapies: The Orals Mariko Kita, MD Section Head, Neurology Section, Virginia Mason Medical Center Director, Virginia Mason Multiple Sclerosis Center Neurology Clinical
More informationTechnology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493
Cladribine tablets for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493 NICE 2018. All rights reserved. Subject to Notice
More informationHorizon Scanning Centre July Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line
Horizon Scanning Centre July 2014 Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line SUMMARY NIHR HSC ID: 2635 This briefing is based on information available
More informationChanging EDSS progression in placebo cohorts in relapsing MS:
Changing EDSS progression in placebo cohorts in relapsing MS: A systematic review and meta-regression Christian Röver 1, Richard Nicholas 2, Sebastian Straube 3, Tim Friede 1 1 Department of Medical Statistics,
More informationCarolyn Taylor, M.D. Swedish Neuroscience Center
Carolyn Taylor, M.D. Swedish Neuroscience Center When should disease modifying therapy be discontinued in MS? Should we be using aggressive treatments earlier in the MS disease course and reserving the
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPATCH Analysis Plan v1.2.doc Prophylactic Antibiotics for the Treatment of Cellulitis at Home: PATCH Analysis Plan for PATCH I and PATCH II Authors: Angela Crook, Andrew Nunn, James Mason and Kim Thomas,
More informationLong-term results of the first line DMT depend on the presence of minimal MS activity during first years of therapy: data of 15 years observation
Boyko Multiple Sclerosis and Demyelinating Disorders (2016) 1:14 DOI 10.1186/s40893-016-0015-x Multiple Sclerosis and Demyelinating Disorders RESEARCH ARTICLE Open Access Long-term results of the first
More informationInternational Journal of MS Care
Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE) Edward J. Fox, MD, PhD; Alberto Vasquez,
More information